|Title||Antibodies in HIV-1 vaccine development and therapy.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC|
Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope for a protective immunization. Renewed optimism in this area of research comes in part from the results of a recent vaccine trial and the use of single-cell antibody-cloning techniques that uncovered naturally arising, broad and potent HIV-1-neutralizing antibodies (bNAbs). These antibodies can protect against infection and suppress established HIV-1 infection in animal models. The finding that these antibodies develop in a fraction of infected individuals supports the idea that new approaches to vaccination might be developed by adapting the natural immune strategies or by structure-based immunogen design. Moreover, the success of passive immunotherapy in small-animal models suggests that bNAbs may become a valuable addition to the armamentarium of drugs that work against HIV-1.
|Grant List||AI 100148-01 / AI / NIAID NIH HHS / United States |
AI 100663-01 / AI / NIAID NIH HHS / United States
UM1AI100663 / AI / NIAID NIH HHS / United States
/ / Howard Hughes Medical Institute / United States
Antibodies in HIV-1 vaccine development and therapy.